- Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Müller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VK, Poeck H, Dong N, Holtick U, Ram R, Pabst T, Shumilov E, Lenz G, Iacoboni G, Barba P, Bücklein VL, Subklewe M. Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers. Blood Adv. 2025 Oct 22:bloodadvances.2025017766. doi: 10.1182/bloodadvances.2025017766. Epub ahead of print. PMID: 41124666.
Stein, J., Anand, P., Abdulmajid, J., Hartz, A., Unterfrauner, M., Feng, X., Schmieder, N., Kruk, L., Bojko, P., Schmohl, J., Schmid, C., Filippini Velázquez, G., & Schmetzer, H. M. (2025). Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML. International Journal of Molecular Sciences, 26(21), 10336. doi.org/10.3390/ijms262110336
Feng, X.; Filippini Velázquez, G.; Bohlscheid, S.; Unterfrauner, M.; Anand, P.; Rejeski, H.A.; Hartz, A.; Baudrexler, T.; Schmid, C.; Schmetzer, H.M. Dendritic Cells of Leukemic Origin (DCleu) Modulate the Expression of Inhibitory Checkpoint Molecules and Their Ligands on T Cells and Blasts in AML Relapse After Allogeneic Stem Cell Transplantation. Cancers2025, 17, 2948. doi.org/10.3390/cancers17182948
Filippini Velázquez, G., Anand, P., Abdulmajid, J. et al. Clinical stabilization of a highly refractory acute myeloid leukaemia under individualized treatment with immune response modifying drugs by in vivo generation of dendritic cells of leukaemic origin (DCleu) and modulation of effector cells and immune escape mechanisms. Biomark Res 13, 104 (2025). doi.org/10.1186/s40364-025-00817-8
Velázquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, Lengerke C, Bethge W, Trepel M, Müller G, Christopeit M, Schmid C. Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment. Haematologica. 2025 Apr 24. doi: 10.3324/haematol.2024.287206. Epub ahead of print. PMID: 40270206.
Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher AS, Schultze-Florey CR, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf GG, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk FA, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Blood Adv. 2025 Apr 16:bloodadvances.2024015719. doi: 10.1182/bloodadvances.2024015719. Epub ahead of print. PMID: 40238938.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Epub ahead of print. PMID: 39661985.
Sauerer, T.*, Velázquez, G.F.* & Schmid, C. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 22, 180 (2023). doi.org/10.1186/s12943-023-01889-6
Filippini Velázquez G, Labopin M, Tischer J, Raiola A, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C, Kröger N, Díez-Martin J, Kwon M, Nagler A, Schmid C, Ciceri F, Mohty M. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukemia - a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023
Unterfrauner M, Rejeski HA, Hartz A, Bohlscheid S, Baudrexler T, Feng X, Rackl E, Li L, Rank A, Filippini Velázquez G, Schmid C, Schmohl J, Bojko P, Schmetzer H. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture. Int J Mol Sci. 2023 Dec 13;24(24):17436. doi: 10.3390/ijms242417436. PMID: 38139264; PMCID: PMC10743754.
Filippini Velázquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, Klinkhammer-Schalke M, Illerhaus G, Schlitt HJ, Anthuber M, Kröncke T, Messmann H, Märkl B, Schmid C, Trepel M, Müller G, Claus R, Hackanson B. Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer. ESMO Open. 2022 Jun;7(3):100470. doi: 10.1016/j.esmoop.2022.100470. Epub 2022 Apr 20. PMID: 35461024; PMCID: PMC9271475.
Mayr P, Grünewald T, Filippini Velazquez G, Rank A, Schmid C, Harloff M, Märkl B, Trepel M, Hirschbühl K, Pfeiffer T, Claus R. Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy. Br J Haematol. 2022 Jun;197(5):627-630. doi: 10.1111/bjh.18064. Epub 2022 Feb 6. PMID: 35128629.
Reese J, Velazquez GF, Weckenbrock J, Kolb G. Behandlung einer sekundären akuten myeloischen Leukämie mit Azacitidin: Erhalt von Lebensqualität und Selbstständigkeit im fortgeschrittenen Lebensalter [Treatment of secondary acute myeloid leukemia with azacitidine: Maintenance of quality of life and independence in advanced age]. Z Gerontol Geriatr. 2020 Jul;53(4):362-364. German. doi: 10.1007/s00391-020-01729-y. Epub 2020 Apr 30. PMID: 32355997.
G. Filippini V Velázquez et al. SECOND ALLOGENEIC SCT (ALLOSCT2) FOR AML IN ACTIVE DISEASE: FEASIBILITY, OUTCOME, AND RISK FACTORS - A STUDY ON BEHALF OF THE ALWP OF THE EBMT – Abstract 1270. Accepted for oral presentation at the 51th Annual Meeting of the European Society for Blood and Marrow Transplantation (Florence, 2025)
G. Filippini Velázquez et al. ANALYSIS OF CHARACTERISTICS, OUTCOME AND RISK FACTORS OF PATIENTS WITH MDS UNDERGOING A SECOND ALLOGENEIC SCT (ALLOSCT2) – A STUDY ON BEHALF OF THE CMWP. Abstract 1530. Accepted for oral presentation at the 51th Annual Meeting of the European Society for Blood and Marrow Transplantation (Florence, 2025)
Giuliano Filippini Velázquez, Jacques-Emmanuel Galimard, Alexandros Spyridonidis, Jakob Passweg, Didier Blaise, Nikolaus Kröger, Igor Wolfgang Blau, Patrice Chevallier, Tobias Gedde-Dahl, Panagiotis Kottaridis, Johan Maertens, Emma Nicholson, Arancha Bermudez Rodriguez, Peter Dreger, Gerald G. Wulf, Mareike Verbeek, Emanuele Angelucci, Mathias Eder, Uwe Platzbecker, Bipin Savani, Christoph Schmid, Fabio Ciceri, Mohamad Mohty. Evaluation of the Transplant Conditioning Intensity (TCI) Score for second allogeneic stem cell transplantation (alloSCT2) - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (2024): Physicians – Poster Session.
G. Filippini Velázquez et al. Digital spatial profiling (DSP) for the assessment of molecular mechanisms involved in extramedullary relapse of acute myeloid leukaemia (eAML) after allogeneic stem cell transplantation. Abstract 163 (Poster). Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Oncology (Basel 2024)
G. Filippini Velázquez et al., EXTRAMEDULLARY RELAPSE OF AML AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CLINICAL MANIFESTATIONS, TREATMENT MODALITIES AND OUTCOME. Abstract PB2514 (ePoster). EHA Annual Meeting (Madrid 2024)
P. Anand*, G. Filippini Velázquez *, J. Abdulmajid, X. Feng, K. Hirschbuehl, A. Sinha, C. Schmid*, H. Schmetzer*. Treatment with blast-modulatory response modifiers induced specific immune responses and led to disease stabilization in a patient with refractory AML after second allogeneic SCT. The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (2024): Physicians – ePoster Session.
Xiaojia Feng*, Giuliano Filippini Velázquez*, Sophia Bohlscheid, Christoph Schmid, Helga Schmetzer. P022: Potential modification of dysregulated expressions of inhibitory checkpoint (ICM) and their ligands on T cells and Blasts in AML relapses after stem cell transplantation (SCT). The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P708). Bone Marrow Transplant 58 (Suppl 1), 153–627 (2023). doi.org/10.1038/s41409-023-02056-7
Filippini Velázquez G; Aslan, H; Baudrexler, T; Schmetzer, H; Schmid, C. P475: Control leukemia by inducing anti-cancer immune reactivity in vivo? Potential of a DC-triggered mechanism. HemaSphere 6:S3 p 721-722, June 2022. doi: 10.1097/01.HS9.0000852292.38263.b8.
Bohlscheid, S.,*; Filippini Velázquez*, G.; Aslan, H.; Baudrexler, T.; Schmetzer, H.; Schmid, C. P1309: Dysregulated expressions of inhibitory checkpoint molecules and their ligands on T-cells and blasts in AML relapses after stem cell transplantation (SCT) HemaSphere 6:S3:p 1194-1195, June 2022. doi: 10.1097/01.HS9.0000848100.61250.11.
